Y-mabs Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Paradigm BioCapital Advisors and its affiliates have reported a complete divestment of their beneficial ownership in Y-mAbs Therapeutics, Inc. common stock.
Caligan Partners LP and David Johnson have reported a complete divestment of their beneficial ownership in Y-mAbs Therapeutics, Inc., now holding 0% of the common stock.
Beryl Capital Management and its affiliates have reported a complete divestment of their beneficial ownership in Y-mAbs Therapeutics, Inc., reducing their stake to 0%.
Glazer Capital, LLC and Paul J. Glazer have filed an amended Schedule 13G indicating they no longer beneficially own shares of Y-mAbs Therapeutics, Inc.
Acorn Bioventures and related entities, including Anders Hove, have disclosed a combined 6.2% beneficial ownership stake in Y-mAbs Therapeutics, Inc.
Glazer Capital and Paul J. Glazer have reported a beneficial ownership of 5.84% in Y-mAbs Therapeutics, Inc., totaling 2,654,700 shares of common stock.
Acorn Bioventures and related entities, including Anders Hove, have increased their beneficial ownership in Y-mAbs Therapeutics, Inc. to 7.0% of outstanding common stock.
Beryl Capital Management and its affiliates have disclosed a 9.0% beneficial ownership stake in Y-mAbs Therapeutics, Inc. common stock.
Investment firm Caligan Partners LP and its Managing Partner David Johnson have disclosed a passive 5.2% beneficial ownership stake in Y-mAbs Therapeutics, Inc., holding 2,342,609 shares of common stock.